Company Profile
Oxford Biomedica plc, a contract development and manufacturing organization focuses on delivering therapies to patients globally. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems InAAVate, a proprietary ยplug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies.
The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and viral vector types. Incorporated in 1996 and headquartered in Oxford, the United Kingdom, Oxford Biomedica was formerly known as Pinco 838 Limited before rebranding in October 1996.